Share on LinkedInShare on LinkedIn

ARTICLE · 15 JULY 2025

EU Consults On New GMP Rules For AI In Pharma Manufacturing

Arnold & Porter
Arnold & Porter
Contributor
Arnold & Porter

Arnold & Porter

With over 1,000 lawyers across 16 offices worldwide, Arnold & Porter is renowned for its...

View firm profile
Explore more from Arnold & Porter

On 7 July 2025, the European Commission launched a public consultation that could mark the start of a turning point for how Artificial Intelligence (AI) is used in pharmaceutical manufacturing.

European UnionTechnology

On 7 July 2025, the European Commission launched a public consultation that could mark the start of a turning point for how Artificial Intelligence (AI) is used in pharmaceutical manufacturing. The consultation proposes significant updates to the EU Good Manufacturing Practice (GMP) guidelines—specifically Chapter 4 on Documentation, Annex 11 on Computerised Systems, and, for the first time, a new Annex 22 dedicated to AI.

The proposals reflect regulators' growing recognition that AI is rapidly becoming part of the pharmaceutical manufacturing landscape. From process optimisation to quality control, AI is expected to bring efficiency and insights that traditional systems can't always deliver. Yet the European Medicines Agency ("EMA") and the Euroean Commission are aware that these same technologies also potentially bring new risks (which may, to an extent, be unforeseeable) —especially when it comes to patient safety, product quality, and data integrity.

We operate a free-to-view policy, asking only that you register in order to read all of our content. Please login or register to view the rest of this article.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

See more popular content from